Drugs / edrecolomab
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00002664 | Jul 1995 → Feb 2017 | colorectal cancer | James Ahlgren | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 32 trials | ||||||
| Phase 3 | NCT00309517 | Jul 1997 → ? | rectal carcinoma | Austrian Breast & Colorectal Cancer Study Group | Terminated | No outcome recorded |
| Phase 3 | NCT00002968 | May 1997 → Jul 2003 | colon mucinous adenocarcinoma, colon signet ring cell adenocarcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | edrecolomab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00002968 ↗ |
| Known as | 17-1A | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108955 ↗ |
| Known as | MAb 17-1A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00309517 ↗ |
| Known as | MOAB 17-1A | “Colorectal antigen 17-1A murine monoclonal antibody, MOAB 17-1A, NSC-377963; Granulocyte-macrophage colony stimulating factor (Immunex), GM-CSF, NSC-613795.” NCT00002664 ↗ |
| Known as | NSC-377963 | “Colorectal antigen 17-1A murine monoclonal antibody, MOAB 17-1A, NSC-377963; Granulocyte-macrophage colony stimulating factor (Immunex), GM-CSF, NSC-613795.” NCT00002664 ↗ |
| Known as | Panorex | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108955 ↗ |
| Modality | Monoclonal antibody | “Colorectal antigen 17-1A murine monoclonal antibody” NCT00002664 ↗ |
| Target | EPCAM | “Epithelial cell adhesion molecule cross-linking agent” CHEMBL2108955 ↗ |